Its a little bit of like, The Devil and Daniel Webster, Dillon told Flow Space
This analysis suggests that the greater effects of tirzepatide may allow more individuals to achieve glycaemic and non-glycaemic therapeutic targets
However, as of May 2026, no peer-reviewed publication has yet demonstrated these effects for retatrutide in Phase 3
CVD Safety Semaglutide has a well-established FDA approval for reducing the risk of major adverse cardiovascular events (MACE) in high-risk patients, based on the SELECT trial which demonstrated a 20% reduction in MACE over a mean 39.8-month follow-up
Preclinical data strongly map these peptides to enhanced barrier function, mucosal proliferation, and local immunomodulation
You might have to remind yourself to eat, which feels strange if youre used to constant hunger